Novo Nordisk shares drop 10% after poor weight loss trial result
Unlock the Editor’s Digest at no cost Roula Khalaf, Editor of the FT, selects her favorite tales on this weekly publication. Novo Nordisk has stated a trial for its once-a-week weight loss injection has fallen wanting its goal, sending the Danish drugmaker’s shares 10 per cent decrease on Monday. The 84-week trial discovered that Novo’s…